GenScript Biotech Corporation (GENSCRIPT) income statement
HKSE · Healthcare · Biotechnology · 6,135 employees · CEO Weihui Shao
- Price
- $3.54 0.0%
- Market cap
- $7.97B
- Enterprise value
- $8B Data as of 2026-11-21
- Last report
- Q2 '26 filed 2026-06-30
- Next report
- 2027-03-24
GenScript Biotech Corporation (GENSCRIPT) reported revenue of $403M for Q2 '26 (-22.3% year on year), operating income of $49.4M (12.3% of revenue) and net income of -$129M. Over the last two half-years revenue was $844M.
Income statement
| Income statement | Trend | Q4 '20 | Q2 '21 | Q4 '21 | Q2 '22 | Q4 '22 | Q2 '23 | Q4 '23 | Q2 '24 | Q4 '24 | Q2 '25 | Q4 '25 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $224M | $230M | $261M | $310M | $316M | $391M | $448M | $285M | $309M | $519M | $441M | $403M | |
| Cost of revenue | $76.7M | $90.9M | $117M | $141M | $181M | $216M | $214M | $152M | $171M | $198M | $208M | $197M | |
| Gross profit | $148M | $139M | $144M | $168M | $136M | $175M | $235M | $134M | $139M | $321M | $233M | $206M | |
| Research & development | $148M | $175M | $183M | $178M | $212M | $207M | $225M | $24.9M | $28.9M | $31.3M | $39.9M | $39.3M | |
| Sales & marketing | $66.3M | $58.3M | $110M | $86.9M | $81.4M | $81.4M | $92.9M | $43.1M | $45.1M | $47.5M | $52M | $0 | |
| General & administrative | $54M | $56.3M | $78.2M | $79.6M | $103M | $107M | $107M | $52.7M | $61.6M | $63.1M | $65.4M | $0 | |
| Operating expenses | $278M | $288M | $516M | $399M | $336M | $398M | $428M | $125M | $138M | $142M | $156M | $157M | |
| Operating income | -$120M | -$152M | -$227M | -$177M | -$261M | -$223M | -$193M | $8.95M | $331K | $179M | $76.2M | $49.4M | |
| Interest income | $6.79M | $1.14M | $5.32M | $1.07M | $3.18M | $13.5M | $32.2M | $101M | $28.9M | $711K | $16.2M | $7.9M | |
| Interest expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $8.03M | $0 | $8.11M | $6.38M | |
| Total non-operating income | -$4.01M | $2.1M | -$140M | -$52.5M | $58.8M | -$22.1M | $86.9M | -$137M | -$43.2M | -$179M | -$547M | -$169M | |
| Income before tax | -$124M | -$150M | -$367M | -$230M | -$202M | -$245M | -$106M | -$128M | -$42.9M | -$119K | -$470M | -$119M | |
| Income tax | -$2.94M | $5.93M | -$4.96M | $3.81M | -$7.53M | $1.1M | $3.04M | $9.81M | $6.84M | $24.4M | $37.4M | $9.9M | |
| Net income | -$91.9M | -$91.1M | -$268M | -$136M | -$91.3M | -$93.6M | -$1.9M | -$175M | $3.14B | -$25.5M | -$507M | -$129M | |
| EPS (basic) | -$0.05 | -$0.05 | -$0.13 | -$0.06 | -$0.04 | -$0.04 | -$0.00 | -$0.05 | $0.01 | -$0.01 | -$0.24 | -$0.06 | |
| EPS (diluted) | -$0.05 | -$0.05 | -$0.13 | -$0.06 | -$0.04 | -$0.04 | -$0.00 | -$0.05 | $0.01 | -$0.02 | -$0.23 | -$0.06 | |
| Shares (basic, weighted) | 1.92B | 1.98B | 2.08B | 2.09B | 2.1B | 2.11B | 1.99B | 2.12B | 2.18B | 1.18B | 2.18B | 2.19B | |
| Shares (diluted, weighted) | 1.92B | 1.98B | 2.09B | 2.09B | 2.1B | 2.11B | 2.11B | 2.12B | 2.18B | 2.16B | 2.23B | 2.19B | |
| Depreciation & amortization | $18.8M | $23M | $24.7M | $30M | $34.3M | $35.5M | $38.4M | $29.6M | $21.3M | $35M | $39.2M | $40.4M | |
| EBITDA | -$101M | -$129M | -$202M | -$147M | -$226M | -$187M | -$155M | $38.5M | $21.6M | $214M | $115M | $89.9M |
| Income statement | Trend | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $115M | $153M | $231M | $273M | $391M | $490M | $626M | $560M | $594M | $960M | |
| Cost of revenue | $38.5M | $48.1M | $72.5M | $93.1M | $135M | $208M | $322M | $290M | $322M | $406M | |
| Gross profit | $76.2M | $105M | $159M | $180M | $256M | $283M | $304M | $271M | $272M | $553M | |
| Research & development | $9.47M | $18.1M | $74.1M | $186M | $263M | $358M | $390M | $52.7M | $53.8M | $71.2M | |
| Sales & marketing | $20.9M | $24.9M | $38.8M | $70.4M | $107M | $168M | $168M | $80.1M | $88.1M | $99.5M | |
| General & administrative | $30.4M | $22M | $40.6M | $55.3M | $90.3M | $135M | $182M | $107M | $114M | $129M | |
| Other operating expenses | -$60K | -$7.35M | -$36K | -$10.1M | $0 | $0 | -$138K | $0 | $0 | $0 | |
| Operating expenses | $44M | $67.1M | $146M | $302M | $460M | $662M | $742M | $244M | $263M | $298M | |
| Operating income | $24.9M | $39.6M | $5.11M | -$131M | -$205M | -$379M | -$438M | $26.2M | $9.28M | $255M | |
| Interest income | $276K | $988K | $9.95M | $8.35M | $6.59M | $2.79M | $13.2M | $73.2M | $28.9M | $26.1M | |
| Interest expense | $10K | $0 | $0 | $781K | $0 | $2.38M | $13.3M | $27.5M | $8.03M | $17.3M | |
| Other non-operating income (gains on investments, FX ...) | $0 | $0 | $0 | -$10.5M | $0 | $136M | $0 | $0 | $0 | $0 | |
| Total non-operating income | $7.58M | -$1.07M | $17.6M | $9.69M | -$77.4M | -$138M | $6.29M | $143M | -$180M | -$726M | |
| Income before tax | $32.5M | $38.5M | $22.7M | -$114M | -$282M | -$517M | -$432M | $169M | -$171M | -$471M | |
| Income tax | $5.97M | $11.5M | $1.94M | $3.83M | -$477K | $964K | -$3.72M | $6.01M | $2.98M | $61.9M | |
| Net income | $26.2M | $26.1M | $21.2M | -$96.9M | -$205M | -$359M | -$227M | -$95.5M | $2.96B | -$533M | |
| EPS (basic) | $0.02 | $0.02 | $0.01 | -$0.05 | -$0.11 | -$0.18 | -$0.11 | $0.20 | -$0.03 | -$0.25 | |
| EPS (diluted) | $0.02 | $0.02 | $0.01 | -$0.05 | -$0.11 | -$0.18 | -$0.11 | $0.20 | -$0.03 | -$0.25 | |
| Shares (basic, weighted) | 1.67B | 1.71B | 1.79B | 1.85B | 1.9B | 2.03B | 2.1B | 2.11B | 2.18B | 2.17B | |
| Shares (diluted, weighted) | 1.71B | 1.73B | 1.84B | 1.85B | 1.9B | 2.03B | 2.1B | 2.11B | 2.18B | 2.19B | |
| Depreciation & amortization | $5.39M | $7M | $12.9M | $20.6M | $32.9M | $47.8M | $64.2M | $74M | $73.9M | $74M | |
| EBITDA | $30.3M | $46.6M | $18M | -$92.3M | -$172M | -$467M | -$374M | $100M | $83.2M | $329M |
Standardised from the company's filings; outflows and costs keep the sign the provider reports. Hover a period for its end date. Amounts in USD.
Revenue, operating income and growth
quarterlyMargins
quarterlyCosts as % of revenue
quarterlyThe other statements
Sources
Statements, segment revenue, metrics and estimates are standardised from the company's filings.
Data as of 2026-11-21